18F-FAPI-42 PET/CT enhances the diagnostic efficacy for peritoneal metastasis of colorectal cancer and guides treatment decisions: an original retrospective study Authors: Xuneng Zhang, Rongqin Zhang, Qingyang Zheng, Zichuan He, Bing Lan, Yun Zhong, Zhichao Huang, Wei Fan, Hui Wang, Keli Yang, Zhanwen Zhang, Huaiming Wang Published: 2024 ABSTRACT AbstractBackgroundColorectal cancer is the third-most common type of cancer. When peritoneal metastasis (PM) develops, diagnosing metastatic lesions is difficult and the prognosis is poor. This study aimed to compare the value of fluorine-18 fibroblast activation protein-specific inhibitor (18F-FAPI-42) and fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) for detecting PM of colorectal cancer and to guide clinical decision-making.MethodsForty-eight patients with PM who underwent both 18F-FAPI-42 and 18F-FDG PET/CT examinations were studied. The maximum standardized uptake value (SUV max), tumor-to-background ratios (TBRs) and peritoneal cancer index (PCI) of the PM were compared between the two imaging techniques. The intraclass correlation coefficient (ICC) was used to compare the consistency between the PET/CT PCI score and the intraoperative PCI. A receiver-operating characteristic curve was used to predict the accuracy of CC-0 cytoreduction (complete cytoreduction with no visible disease).ResultsThe sensitivity and accuracy of 18F-FAPI-42 PET/CT for detecting PM were higher than those of 18F-FDG PET/CT (82.1% vs 61.1%, P < 0.01; 84.6% vs 74.5%, P < 0.01). The median SUV max and TBR of PM was greater in 18F-FAPI-42 than in 18F-FDG PET/CT [4.8 (1.9–20.1) vs 4.7 (1.0–11.0), P = 0.02; 4.3 (1.4–14.6) vs 2.9 (0.6–8.0), P < 0.01, respectively]. The median PCI of PM based on 18F-FAPI-42 PET/CT was greater than that based on 18F-FDG PET/CT (15 vs 9, P < 0.01). The ICC for 18F-FAPI-42 PCI was greater than that for 18F-FDG PCI (0.915 vs 0.724, P < 0.01). The cut-off values of the PCI of the PM for 18F-FAPI-42 and 18F-FDG PET/CT to predict CC-0 were <18 and <10, with areas under the curve of 0.80 and 0.79, respectively.Conclusions 18F-FAPI-42 PET/CT has superior diagnostic efficacy for PM, particularly in the right upper epigastrium and small intestine. The PCI score of 18F-FAPI-42 PET/CT is very close to the intraoperative PCI score and has a high value for predicting CC-0. The individualized management of PM based on the 18F-FAPI-42 PET/CT PCI score is pivotal.Keywords: colorectal cancer, peritoneal metastasis, 18F-FAPI-42 PET/CT, PCI Introduction Colorectal cancer is the third-most common cancer and the second-leading cause of cancer-related deaths. It is the third-most common cancer in females and the second-most common cancer in males [1]. The prognosis for localized early-stage colorectal cancer is favorable; however, the prognosis for patients who develop distant metastasis is poor [2]. The prognosis for patients with peritoneal carcinomatosis (PC) is usually considered poor, with a median survival of 6–9 months [3, 4]. With the advancements in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), the long-term survival of select patients with colorectal peritoneal metastases (PMs) has improved [5, 6]. The assessment of the extent of PC via the peritoneal cancer index (PCI) described by Sugarbaker is particularly important for cytoreductive surgery [7]. Compared with traditional imaging techniques, fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) has shown improved diagnostic efficacy in detecting PC in patients with colorectal cancer [8]. However, 18F-FDG PET/CT also has certain limitations, including low specificity and low detection rates for the non-intestinal diffuse type, mucous cancer, and carcinomas containing signet-ring cells [9]. 18F-FDG PET/CT also has low to moderate sensitivity for lymph node staging, limiting its utility in the staging and surgical planning of gastro-intestinal cancers [8, 9]. Furthermore, the evaluation of 18F-FDG uptake by intestinal lesions is also hindered by the physiological uptake of 18F-FDG in the intestine [10]. Fibroblast activation protein (FAP) is strongly expressed on the cancer-associated fibroblasts of many epithelial cancers, with minimal expression in healthy adult tissues, and is a key player in tumor progression [9, 11]. FAP-specific inhibitors (FAPIs) were initially developed as anticancer drugs and have since been developed into tumor-targeting radiopharmaceuticals, gradually being used in PET/CT for the diagnosis of various solid tumors and metastatic tumors [12, 13]. Compared with 18F-FDG, 68Ga-FAPI exhibits less physiological uptake, a higher tumor-to-background ratio (TBR), and more rapid renal clearance, offering superior diagnostic efficacy in abdominal and pelvic imaging, particularly for peritoneal carcinoma sites such as the omentum, mesentery, bowel wall, and pelvis [9, 10, 14]. Previous studies have suggested that FAPI PET/CT is superior to FDG PET/CT in diagnosing PMs of colorectal cancer, but they have provided only a preliminary analysis of a few peritoneal metastatic lesions [10, 15–17]. There is a lack of detailed research specifically on the use of FAPI PET/CT for diagnosing PMs in patients with colorectal cancer. In this study, the diagnostic performance of 18F-FAPI-42 PET/CT and that of 18F-FDG PET/CT for PMs of colorectal cancer were analysed by comparing the PCI scores indicated by the two types of PET/CT with the PCI scores from surgery. Additionally, the enrolled patients were followed up, and survival information was obtained to assess the applicability of 18F-FAPI-42 PET/CT for assisting surgeons in making precise treatment decisions. Patients and methods Patients This retrospective clinical study included data from 48 patients who were diagnosed with colorectal cancer with synchronous or metachronous PM and who underwent 18F-FDG PET/CT and 18F-FAPI-42 PET/CT examinations between December 2022 and August 2023. The inclusion criteria for patients with synchronous PM were as follows: (i) age <75 years; (ii) colonoscopy pathology had confirmed colorectal cancer and other imaging findings suggested suspicious PM; (iii) 18F-FDG PET/CT and 18F-FAPI-42 PET/CT were used for tumor staging; and (iv) the patients underwent cytoreductive surgery or laparoscopic exploration. The inclusion criteria for patients with metachronous PM were as follows: (i) age <75 years; (ii) previous pathology had confirmed the primary colorectal cancer and other imaging findings suggested suspicious PM; (iii) 18F-FDG PET/CT and 18F-FAPI-42 PET/CT were used for restaging of the tumor and to confirm the absence of other distant metastases; and (iv) the patients underwent cytoreductive surgery or laparoscopic exploration. The exclusion criteria were as follows: (i) age ≥75 years; (ii) severe co-morbidities; (iii) other primary malignancies; (iv) pregnancy or the presence of other severe non-malignant diseases; (v) presence of other distant metastases; or (vi) diabetes. Radiopharmaceutical and image acquisition 18F-FDG and 18F-FAPI-42 were obtained from Guangdong Cyclotron Medical Science Co., Ltd (Guangzhou, China). The radiochemical purity of the final products was >95%. 18F-FDG and 18F-FAPI-42 PET/CT were performed on 2 different days within 1 week. Between the two PET/CT scans, the patients did not receive any antitumor treatments. Patients fasted for 4–6 hours and a blood glucose level of <10 mmol/L was confirmed before 18F-FDG PET/CT examination. For the 18F-FAPI-42 PET/CT examination, no fasting was needed. Data were acquired via a PET/CT scanner (uMI780, United Imaging Healthcare, Shanghai, China) 45–60 min after injection of 3.5–5.5 MBq/kg of 18F-FDG or about 3.7 MBq/kg of 18F-FAPI-42. A CT scan was performed from the skull base to the upper thigh, and the head scan was performed separately (for 18F-FDG) or from the head to the upper thigh (for 18F-FAPI-42). The following parameters were used for the CT scan: tube voltage, 120 kV; current, 200 mA; and slice thickness, 3.00 mm. PET was then performed with the patient in the same bed position as for the CT scan with five or six bed positions and 2 min/position in 3D acquisition mode. All the obtained data were transferred to the uWS-MI Workstation (United Imaging Healthcare, Shanghai, China). Positron emission tomography data were reconstructed using the ordered subset expectation maximization algorithm (2 iterations and 20 subsets) and CT data were used for PET attenuation correction. The reconstructed images were then co-registered and displayed. Image analysis The images were independently analysed by two experienced nuclear medicine physicians. Any discrepancies were resolved through discussion to reach a final consensus. Image interpretation included visual analysis and quantitative assessment. After the exclusion of physiological uptake and benign lesions, any focal accumulation of 18F-FDG and 18F-FAPI-42 that was higher than in the surrounding soft tissues or the contralateral normal tissues was interpreted as positive for visual analysis. For semi-quantitative analysis, the regions of interest (ROIs) were manually drawn around the lesion on the PET images and the maximum standardized uptake value (SUV max) of PMs were recorded on both 18F-FDG and 18F-FAPI-42 PET/CT. To obtain the paired SUV max of the metastatic lesion on both 18F-FDG and 18F-FAPI-42 PET/CT, if a lesion was positive on 18F-FAPI-42 PET/CT but negative on 18F-FDG PET/CT, the ROI of the SUV max on 18F-FDG PET/CT was set according to the same region on 18F-FAPI-42 PET/CT or vice versa. The tumor-to-background (T/B) ratio was also recorded by dividing the SUV max of the metastatic lesion by the SUV mean of the aortic arch on both 18F-FDG and 18F-FAPI-42 PET/CT. The preoperative PCI established by Sugarbaker was calculated on both 18F-FDG and 18F-FAPI-42 PET/CT to evaluate the extent of the PMs. Surgery All enrolled patients underwent laparoscopic exploration or CRS. The surgical procedures for all enrolled patients were collectively performed by the same three senior surgeons. The entire abdominal and intestinal regions were divided into 13 regions and the PCI score established by Sugarbaker was calculated (Supplementary Figure S1). For all patients who achieved complete cytoreduction, tumor tissues were biopsied according to the specific compartments and all patients underwent HIPEC and intravenous chemotherapy postoperatively. For patients who did not achieve CC-0 cytoreduction, the PCI score was jointly documented by the lead surgeon and assistant during surgery, and all patients underwent regular palliative chemotherapy postoperatively. At least one dedicated surgical oncologist participated in all surgical procedures. Reference standards The overall survival (OS) was calculated from the date of CRS to the event of death from any cause and was censored at the most recent time at which the patient was known to be alive. Progression-free survival (PFS) was calculated from the date of CRS to the earliest date of disease progression or death from any cause and was censored at the most recent time at which the patient was confirmed to be alive without disease progression. The presence and characteristics of tumor lesions indicated by PET/CT imaging were compared with surgical exploration results or histopathological findings, with the latter being the ultimate diagnostic benchmark. Subsequent follow-ups were conducted by using CT or PET/CT scans. The positive criteria were as follows: (i) after antitumor treatments such as radiotherapy, chemotherapy, or immunotherapy, imaging revealed a reduction in the diameter of the lesion compared with its previous state; (ii) there was an increase in the lesion diameter following antitumor treatment; (iii) although the lesion diameter remained largely unchanged post-treatment, PET/CT indicated a decrease in radiotracer uptake compared with that in earlier scans; and (iv) new metastatic lesions were detected during subsequent imaging follow-ups. The negative criteria were as follows: (i) no significant change in tumor diameter was found after antitumor treatments; (ii) PET/CT scans post-treatment showed no significant change in radiotracer uptake at the lesion site; and (iii) imaging results during follow-up suggested no positive changes, indicating the absence of tumor activity. Statistical analysis Statistical analysis was performed by using IBM SPSS software (version 21.0; IBM Corp., Armonk, NY, USA). The Wilcoxon signed-rank test was used to compare the imaging parameters and lesion detection between the two PET/CT modalities in patients as well as between the preoperative PCI and intraoperative PCI scores. Percentages were used to describe categorical variables and the median (range) was used for continuous variables. The chi-square test was used to compare the detection rates of PM tumors between the two PET/CT modalities. The intraclass correlation coefficient (ICC) was used to describe the consistency between the tumor burden indicated by 18F-FAPI-42 PET/CT and 18F-FDG PET/CT and the intraoperative tumor burden. The receiver-operating characteristic (ROC) curve and area under the curve (AUC) were used to describe the performance of 18F-FAPI-42 PET/CT-guided surgery in achieving CC-0 cytoreduction, whereas PFS and OS were used to describe the prognosis of the patients. All the statistical tests were two-sided and P < 0.05 was considered statistically significant. Results Baseline characteristics The patient enrollment process is shown in Figure 1. The baseline characteristics of the 48 included patients are shown in Table 1. Among the enrolled patients, 26 (54.2%) were male and 22 (45.8%) were female; 23 (47.9%) were >50 years of age and 25 (52.1%) were <50 years of age. Among the 48 patients, 37 (77.1%) had colon cancer and 11 (22.9%) had rectal cancer; 9 (18.8%) had synchronous PM and 39 (81.2%) had metachronous PM. In terms of prior treatment, only 1 patient (2.1%) underwent surgical treatment alone, 1 patient (2.1%) received medical treatment alone, 39 patients (81.2%) received a combination of medical and surgical treatment, and 7 patients (14.6%) did not receive any treatment. Study flowchart. 18F = fluorine-18, FAPI = fibroblast activation protein-specific inhibitor, FDG = fluorodeoxyglucose, PET/CT = positron emission tomography/computed tomography. Table 1.Clinical characteristics of 48 patients who underwent 18F-FAPI-42 PET/CT and 18F-FDG PET/CTParameterNo. of patients (%)Sex, n (%) Male26 (54.2) Female22 (45.8)Age, years48 ≥50 years, n (%)23 (47.9) <50 years, n (%)25 (52.1)Previous treatment, n (%) Surgery alone1 (2.1) Medication alone1 (2.1) Both39 (81.2) No treatment7 (14.6)Primary tumor location, n (%) Colon37 (77.1) Rectum11 (22.9)Targeted therapy, n (%) Yes24 (50.0) No24 (50.0)Tumor condition, n (%) Synchronous peritoneal metastasis9 (18.8) Metachronous peritoneal metastasis39 (81.2)Surgery, n (%) CC-0 cytoreduction24 (50.0) No CC-0 cytoreduction24 (50.0) 18F = fluorine-18, FAPI = fibroblast activation protein-specific inhibitor, FDG = fluorodeoxyglucose, PET/CT = positron emission tomography/computed tomography, CC-0 cytoreduction = complete cytoreduction with no visible disease. Clinical characteristics of 48 patients who underwent 18F-FAPI-42 PET/CT and 18F-FDG PET/CT 18F = fluorine-18, FAPI = fibroblast activation protein-specific inhibitor, FDG = fluorodeoxyglucose, PET/CT = positron emission tomography/computed tomography, CC-0 cytoreduction = complete cytoreduction with no visible disease. Comparison of the diagnostic efficacy of 18F-FAPI-42 and 18F-FDG PET/CT for the detection of PM of colorectal cancer The diagnostic efficacy of 18F-FAPI-42 PET/CT and 18F-FDG PET/CT for detecting PM of colorectal cancer in 48 patients who underwent surgery is shown in Table 2. The sensitivity, negative predictive value (NPV), and accuracy of 18F-FAPI-42 PET/CT were significantly greater than those of 18F-FDG PET/CT (82.1% vs 61.1%, P < 0.01; 80.8% vs 66.8%, P < 0.01; 84.6% vs 74.5%, P < 0.01). In the right upper region, the sensitivity, NPV, and accuracy of 18F-FAPI-42 PET/CT were greater than those of 18F-FDG PET/CT (92.9% vs 39.3%, P < 0.01; 90.0% vs 52.8%, P < 0.01; 91.7% vs 62.5%, P < 0.01). In the epigastrium, the sensitivity, NPV, and accuracy of 18F-FAPI-42 PET/CT were also significantly greater than those of 18F-FDG PET/CT (92.9% vs 42.6%, P < 0.01; 90.0% vs 58.8%, P = 0.01; 91.7% vs 66.7%, P < 0.01). In the left flank, the sensitivity of 18F-FAPI-42 PET/CT was greater than that of 18F-FDG PET/CT (95.8% vs 66.7%, P < 0.01). Additionally, in the small intestine, the sensitivity and accuracy of 18F-FAPI-42 PET/CT were greater than those of 18F-FDG PET/CT (59.3% vs 36.0%, P < 0.01; 81.3% vs 70.8%, P < 0.01). Table 2.Comparison of 18F-FDG PET/CT and 18F-FAPI-42 PET/CT in 48 patients with peritoneal metastases who underwent surgeryLocationTrue positiveTrue negativeFalse positiveFalse negativeSensitivity, % (n/N)Specificity, % (n/N)PPV, % (n/N)NPV, % (n/N)Accuracy, % (n/N)CentralFAPI23156485.2(23/27)71.4(15/21) 79.3(23/29) 78.9(15/19) 79.2(38/48) FDG21165677.8(21/27)76.2(16/21) 80.8(21/26) 72.7(16/22) 77.1(37/48) P 0.480.860.890.640.81Right upperFAPI26182292.9(26/28)90.0(18/20) 92.9(26/28) 90.0(18/20) 91.7(44/48) FDG111911739.3(11/28)95.0(19/20) 91.7(11/12) 52.8(19/36) 62.5(30/48) P <0.010.540.89<0.01<0.01EpigastriumFAPI26182292.9(26/28)90.0(18/20) 92.9(26/28) 90.0(18/20) 91.7(44/48) FDG122021446.2(12/26)90.9(20/22) 85.7(12/14) 58.8(20/34) 66.7(32/48) P <0.010.620.450.01<0.01Left upperFAPI19233386.4(19/22)88.5(23/26) 86.4(19/22) 88.5(23/26) 87.5(42/48) FDG16242672.7(16/22)92.3(24/26) 88.9(16/18) 80.0(24/30) 83.3(40/48) P 0.260.630.810.390.56Left flankFAPI23213195.8(23/24)87.5(21/24) 88.5(23/26) 95.5(21/22) 91.7(44/48) FDG16213866.7(16/24)87.5(21/24) 84.2(16/19) 72.4(21/29) 77.1(37/48) P 0.0110.670.030.49Left lowerFAPI26163389.7(26/29)84.2(16/19) 89.7(26/29) 84.2(16/19) 87.5(42/48) FDG23172679.3(23/29)89.5(17/19) 92.0(23/25) 73.9(17/23) 83.3(40/48) P 0.270.630.760.420.56PelvisFAPI32103391.4(32/35)76.9(10/13) 91.4(32/35) 76.9(10/13) 87.5(42/48) FDG30103585.7(30/35)76.9(10/13) 90.9(30/33) 66.7(10/15) 83.3(40/48) P 0.4510.940.540.56Right lowerFAPI25910486.2(25/29)47.4(9/19) 71.4(25/35) 69.2(9/13) 70.8(34/48) FDG25118486.2(25/29)57.9(11/19) 75.8(25/33) 73.3(11/15) 75.0(36/48) P 10.510.680.810.64Right flankFAPI25173389.3(25/28)85.0(17/20) 89.3(25/28) 85.0(17/20) 87.5(42/48) FDG19182967.9(19/28)90.0(18/20) 90.5(19/21) 66.7(18/27) 77.1(37/48) P 0.050.630.890.150.18Small intestineaFAPI51105135 59.3(51/86) 99.1(105/106) 98.1(51/52) 75.0(105/140) 81.3(156/192) FDG31105155 36.0(31/86) 99.1(105/106) 96.9(31/32) 65.6(105/160) 70.8(136/192) P <0.0110.740.07<0.01TotalFAPI2762523660 82.1(276/336) 87.5(252/288) 88.5(276/312) 80.8(252/312) 84.6(528/624) FDG20426129130 61.1(204/334) 90.0(252/290) 87.6(204/233) 66.8(261/391) 74.5(465/624) P <0.010.340.74<0.01<0.01 18F = fluorine-18, FAPI = fibroblast activation protein-specific inhibitor, FDG = fluorodeoxyglucose, PET/CT = positron emission tomography/computed tomography, PPV = positive predictive value, NPV = negative predictive value. In this table, FAPI refers to 18F-FAPI-42 PET/CT, and FDG refers to 18F-FDG PET/CT.aSmall intestine contains the upper jejunum, lower jejunum, upper ileum, and lower ileum. N = The number of cases with either positive or negative pathological findings. n = The number of cases with either positive or negative PET/CT findings.The numbers corresponding to true positive, true negative, false positive, and false negative represent the counts of case numbers. Comparison of 18F-FDG PET/CT and 18F-FAPI-42 PET/CT in 48 patients with peritoneal metastases who underwent surgery 79.3 79.3 (23/29) (23/29) 78.9 78.9 (15/19) (15/19) 79.2 79.2 (38/48) (38/48) 80.8 80.8 (21/26) (21/26) 72.7 72.7 (16/22) (16/22) 77.1 77.1 (37/48) (37/48) 92.9 92.9 (26/28) (26/28) 90.0 90.0 (18/20) (18/20) 91.7 91.7 (44/48) (44/48) 91.7 91.7 (11/12) (11/12) 52.8 52.8 (19/36) (19/36) 62.5 62.5 (30/48) (30/48) 92.9 92.9 (26/28) (26/28) 90.0 90.0 (18/20) (18/20) 91.7 91.7 (44/48) (44/48) 85.7 85.7 (12/14) (12/14) 58.8 58.8 (20/34) (20/34) 66.7 66.7 (32/48) (32/48) 86.4 86.4 (19/22) (19/22) 88.5 88.5 (23/26) (23/26) 87.5 87.5 (42/48) (42/48) 88.9 88.9 (16/18) (16/18) 80.0 80.0 (24/30) (24/30) 83.3 83.3 (40/48) (40/48) 88.5 88.5 (23/26) (23/26) 95.5 95.5 (21/22) (21/22) 91.7 91.7 (44/48) (44/48) 84.2 84.2 (16/19) (16/19) 72.4 72.4 (21/29) (21/29) 77.1 77.1 (37/48) (37/48) 89.7 89.7 (26/29) (26/29) 84.2 84.2 (16/19) (16/19) 87.5 87.5 (42/48) (42/48) 92.0 92.0 (23/25) (23/25) 73.9 73.9 (17/23) (17/23) 83.3 83.3 (40/48) (40/48) 91.4 91.4 (32/35) (32/35) 76.9 76.9 (10/13) (10/13) 87.5 87.5 (42/48) (42/48) 90.9 90.9 (30/33) (30/33) 66.7 66.7 (10/15) (10/15) 83.3 83.3 (40/48) (40/48) 71.4 71.4 (25/35) (25/35) 69.2 69.2 (9/13) (9/13) 70.8 70.8 (34/48) (34/48) 75.8 75.8 (25/33) (25/33) 73.3 73.3 (11/15) (11/15) 75.0 75.0 (36/48) (36/48) 89.3 89.3 (25/28) (25/28) 85.0 85.0 (17/20) (17/20) 87.5 87.5 (42/48) (42/48) 90.5 90.5 (19/21) (19/21) 66.7 66.7 (18/27) (18/27) 77.1 77.1 (37/48) (37/48) 59.3 59.3 (51/86) (51/86) 99.1 99.1 (105/106) (105/106) 98.1 98.1 (51/52) (51/52) 75.0 75.0 (105/140) (105/140) 81.3 81.3 (156/192) (156/192) 36.0 36.0 (31/86) (31/86) 99.1 99.1 (105/106) (105/106) 96.9 96.9 (31/32) (31/32) 65.6 65.6 (105/160) (105/160) 70.8 70.8 (136/192) (136/192) 82.1 82.1 (276/336) (276/336) 87.5 87.5 (252/288) (252/288) 88.5 88.5 (276/312) (276/312) 80.8 80.8 (252/312) (252/312) 84.6 84.6 (528/624) (528/624) 61.1 61.1 (204/334) (204/334) 90.0 90.0 (252/290) (252/290) 87.6 87.6 (204/233) (204/233) 66.8 66.8 (261/391) (261/391) 74.5 74.5 (465/624) (465/624) 18F = fluorine-18, FAPI = fibroblast activation protein-specific inhibitor, FDG = fluorodeoxyglucose, PET/CT = positron emission tomography/computed tomography, PPV = positive predictive value, NPV = negative predictive value. In this table, FAPI refers to 18F-FAPI-42 PET/CT, and FDG refers to 18F-FDG PET/CT. Small intestine contains the upper jejunum, lower jejunum, upper ileum, and lower ileum. N = The number of cases with either positive or negative pathological findings. n = The number of cases with either positive or negative PET/CT findings. The numbers corresponding to true positive, true negative, false positive, and false negative represent the counts of case numbers. The diagnostic efficacy of 18F-FAPI-42 PET/CT and 18F-FDG PET/CT in 24 CC-0 patients is shown in Table 3. The sensitivity of 18F-FAPI-42 PET/CT was significantly greater than that of 18F-FDG PET/CT (72.2% vs 53.5%, P < 0.01). Specifically, the positive predictive value, NPV, and accuracy of 18F-FAPI-42 PET/CT and those of 18F-FDG PET/CT were not significantly different (90.7% vs 90.0%, P = 0.82; 80.4% vs 72.0%, P = 0.19; 86.0% vs 80.2%, P = 0.09; 84.3% vs 78.2%, P = 0.051). Table 3.Comparison of 18F-FDG PET/CT and 18F-FAPI-42 PET/CT in detecting peritoneal metastases in patients with CC-0 resection (n = 24)LocationTrue positiveTrue negativeFalse positiveFalse negativeSensitivity, % (n/N)Specificity, % (n/N)PPV, % (n/N)NPV, % (n/N)Accuracy, % (n/N)CentralFAPI8113280.0 (8/10)78.6 (11/14)72.7 (8/11)84.6 (11/13)79.2 (19/24)FDG7122370.0 (7/10)85.7 (12/14)77.8 (7/9)80.0 (12/15)79.2 (19/24)p1.001.001.001.001.00Right upperFAPI8131280.0 (8/10)92.9 (13/14)88.9 (8/9)86.7 (13/15)87.5 (21/24)FDG21480100.0 (2/2)63.6 (14/22)20.0 (2/10)100.0 (14/14)66.7 (16/24)p1.000.06<0.010.480.08EpigastriumFAPI6141366.7 (6/9)93.3 (14/15)85.7 (6/7)82.4 (14/17)83.3 (20/24)FDG2150722.2 (2/9)100.0 (15/15)100.0 (2/2)68.2 (15/23)70.8 (17/24)p0.151.001.001.000.49Left upperFAPI2172340.0 (2/5)89.5 (17/19)50.0 (2/4)85.0 (17/20)79.2 (19/24)FDG2181340.0 (2/5)94.7 (18/19)66.7 (2/3)85.7 (18/21)83.3 (20/24)p1.001.001.001.001.00Left flankFAPI71520100.0 (7/7)88.2 (15/17)77.8 (7/9)100.0 (15/15)91.7 (22/24)FDG4152357.1 (4/7)88.2 (15/17)66.7 (4/6)83.3 (15/18)79.2 (19/24)p0.191.001.000.230.41Left lowerFAPI8112372.7 (8/11)84.6 (11/13)80.0 (8/10)78.6 (11/14)79.2 (19/24)FDG8112372.7 (8/11)84.6 (11/13)80.0 (8/10)78.6 (11/14)79.2 (19/24)p1.001.001.001.001.00PelvisFAPI1462287.5 (14/16)75.0 (6/8)87.5 (14/16)75.0 (6/8)83.3 (20/24)FDG1262475.0 (12/16)75.0 (6/8)85.7 (14/16)60.0 (6/10)75.0 (18/24)p0.771.001.000.630.72Right lowerFAPI8122280.0 (8/10)85.7 (12/14)80.0 (8/10)85.7 (12/14)83.3 (20/24)FDG6121554.5 (6/11)92.3 (12/13)85.7 (6/7)70.6 (12/17)75.0 (18/24)p0.361.001.000.720.81Right flankFAPI7123277.8 (7/9)80.0 (12/15)70.0 (7/10)85.7 (12/14)79.2 (19/24)FDG5132455.6 (5/9)86.7 (13/15)71.4 (5/7)76.5 (13/17)75.0 (18/24)p0.621.001.000.830.73Small intestineaFAPI107411147.6 (10/21)98.7 (74/75)90.9 (10/11)87.1 (74/85)87.5 (84/96)FDG67411537.5 (6/16)98.7 (74/75)85.7 (6/7)83.1 (74/89)83.3 (80/96)p0.701.000.930.910.83TotalFAPI781851930 72.2(78/108) 90.7(185/204) 80.4(78/97) 86.0(185/215) 84.3(263/312) FDG541902147 53.5(54/101) 90.0(190/211) 72.0(54/75) 80.2(190/237) 78.2(244/312) P<0.010.820.190.090.051 18F = fluorine-18, FAPI = fibroblast activation protein-specific inhibitor, FDG = fluorodeoxyglucose, PET/CT = positron emission tomography/computed tomography, PPV = positive predictive value, NPV = negative predictive value. In this table, FAPI refers to 18F-FAPI-42 PET/CT, and FDG refers to 18F-FDG PET/CT.aSmall intestine contains the upper jejunum, lower jejunum, upper ileum, and lower ileum. N = The number of cases with either positive or negative pathological findings. n = The number of cases with either positive or negative PET/CT findings. The numbers corresponding to true positive, true negative, false positive, and false negative represent the counts of case numbers. Comparison of 18F-FDG PET/CT and 18F-FAPI-42 PET/CT in detecting peritoneal metastases in patients with CC-0 resection (n = 24) 72.2 72.2 (78/108) (78/108) 90.7 90.7 (185/204) (185/204) 80.4 80.4 (78/97) (78/97) 86.0 86.0 (185/215) (185/215) 84.3 84.3 (263/312) (263/312) 53.5 53.5 (54/101) (54/101) 90.0 90.0 (190/211) (190/211) 72.0 72.0 (54/75) (54/75) 80.2 80.2 (190/237) (190/237) 78.2 78.2 (244/312) (244/312) 18F = fluorine-18, FAPI = fibroblast activation protein-specific inhibitor, FDG = fluorodeoxyglucose, PET/CT = positron emission tomography/computed tomography, PPV = positive predictive value, NPV = negative predictive value. In this table, FAPI refers to 18F-FAPI-42 PET/CT, and FDG refers to 18F-FDG PET/CT. Small intestine contains the upper jejunum, lower jejunum, upper ileum, and lower ileum. N = The number of cases with either positive or negative pathological findings. n = The number of cases with either positive or negative PET/CT findings. The numbers corresponding to true positive, true negative, false positive, and false negative represent the counts of case numbers. Comparison of the imaging parameters of 18F-FAPI-42 PET/CT and 18F-FDG PET/CT in PC patients with colorectal cancer Based on patient analysis, the median SUV max and TBR of PC were significantly higher in 18F-FAPI-42 PET/CT than in 18F-FDG PET/CT [SUV max: 4.8 (1.9–20.1) vs 4.7 (1.0–11.0), P = 0.02; TBR: 4.3 (1.4–14.6) vs 2.9 (0.6–8.0), P < 0.01]. On the basis of abdominopelvic region analysis, the median SUV max and TBR of PCs from patients with colorectal cancer were greater on 18F-FAPI-42 PET/CT than on 18F-FDG PET/CT in regions other than the lower left and lower right regions (P < 0.01), as shown in Table 4. Table 4.Comparison of 18F-FDG PET/CT and 18F-FAPI-42 PET/CT with the SUV Max and TBR in surgical patientsLocation of PCI scoreNo. of patientsSUV max Z P FDGFAPI Central272.3 (1.0–7.5)4.0 (1.2–13.1)−3.933<0.011.5 (0.7–6.5)3.2 (0.8–14.6)−4.099<0.01Right upper271.8 (0.8–6.6)2.8 (1.4–10.4)−3.809<0.011.1 (0.4–5.1)2.2 (1.3–11.2)−4.084<0.01Epigastrium231.6 (0.7–5.2)2.7 (1.5–10.3)−4.199<0.011.1 (0.6–4.0)2.2 (1.2–10.4)−4.197<0.01Left upper212.0 (1.0–4.7)3.0 (1.9–10.7)−3.921<0.011.2 (0.7–4.7)2.6 (1.5–9.0)−3.980<0.01Left flank262.2 (0.8–10.2)3.4 (1.1–12.2)−2.4290.011.4 (0.4–6.4)2.8 (0.5–10.2)−3.543<0.01Left lower293.3 (0.9–9.4)3.2 (1.4–10.5)NANA2.0 (0.6–4.8)2.5 (1.1–6.4)−2.5620.01Pelvis342.6 (1.0–10.5)4.3 (1.4–20.1)−2.983<0.011.6 (0.5–8.1)3.3 (0.8–14.4)−2.983<0.01Right lower281.8 (0.5–10.0)3.4 (1.2–15.1)NANA1.5 (0.3–5.6)2.3 (1.2–13.7)−2.4820.01Right flank281.8 (0.5–6.9)3.4 (1.2–9.2)−3.544<0.011.3 (0.5–3.8)2.6 (0.8–10.2)−4.008<0.01Upper jejunum111.3 (0.8–2.6)3.2 (1.2–9.0)−2.758<0.011.0 (0.7–1.6)1.9 (1.0–10.0)−2.756<0.01Lower jejunum102.0 (1.0–9.9)3.9 (1.4–11.0)−1.9880.043.9 (1.4–11.0)2.5 (1.2–12.2)−2.2930.02Upper ileum132.4 (1.1–4.7)4.4 (2.0–13.2)−2.971<0.014.4 (2.0–13.2)3.1 (1.3–14.7)−2.667<0.01Lower ileum182.6 (1.1–11.0)5.8 (1.7–13.2)−2.5920.012.0 (0.8–6.9)3.5 (1.6–12.7)−3.332<0.01Total444.7 (1.0–11.0)4.8 (1.9–20.1)−2.2930.022.9 (0.6–8.0)4.3 (1.4–14.6)−4.049<0.01Unless otherwise stated, the data are presented as medians, and ranges in parentheses. 18F = fluorine-18, FAPI = fibroblast activation protein-specific inhibitor, FDG = fluorodeoxyglucose, PET/CT = positron emission tomography/computed tomography, SUV max = maximum standardized uptake value, TBR = tumor-to-background ratio, PCI = peritoneal cancer index. In this table, FAPI refers to 18F-FAPI-42 PET/CT, and FDG refers to 18F-FDG PET/CT. Comparison of 18F-FDG PET/CT and 18F-FAPI-42 PET/CT with the SUV Max and TBR in surgical patients Unless otherwise stated, the data are presented as medians, and ranges in parentheses. 18F = fluorine-18, FAPI = fibroblast activation protein-specific inhibitor, FDG = fluorodeoxyglucose, PET/CT = positron emission tomography/computed tomography, SUV max = maximum standardized uptake value, TBR = tumor-to-background ratio, PCI = peritoneal cancer index. In this table, FAPI refers to 18F-FAPI-42 PET/CT, and FDG refers to 18F-FDG PET/CT. Assessment of the extent of PC in patients with colorectal cancer The median intraoperative PCI of 48 patients was 16 (2–39) and the PM tumor burdens in different abdominopelvic regions are shown in Supplementary Table S1. The median PCI based on 18F-FAPI-42 PET/CT was significantly greater than that based on 18F-FDG PET/CT [15 (0–39) vs 9 (0–39), P < 0.01], as shown in Figure 2A. Among the 48 patients who underwent surgical treatment, 24 achieved CC-0 cytoreduction and the other 24 achieved non-CC-0 cytoreduction. The median PCIs based on surgery in CC-0 and non-CC-0 patients were 7.5 (2–30) and 29 (0–39), respectively. The median PCIs based on 18F-FAPI-42 PET/CT in CC-0 and non-CC-0 patients were 7.0 (2–30) and 27 (0–39), respectively. The median PCIs based on 18F-FDG PET/CT in CC-0 and non-CC-0 patients were 7.0 (2–30) and 14.5 (0–39), respectively. Comparison of PCI scores from surgery and PET/CT. (A) Comparison of PCI indicated by 18F-FAPI-42 PET/CT and 18F-FDG PET/CT with intraoperative PCI. (B) Analysis of the consistency between the FAPI-42-PCI, FDG-PCI, and Surgery-PCI methods in 48 surgical patients. (C) Consistency analysis of FAPI-42-PCI, FDG-PCI, and Surgery-PCI based on 24 CC-0 patients. (D) Consistency analysis of FAPI-42-PCI, FDG-PCI, and Surgery-PCI based on 24 non-CC-0 patients. PCI = peritoneal cancer index, PET/CT = positron emission tomography/computed tomography, 18F = fluorine-18, FAPI = fibroblast activation protein-specific inhibitor, FDG = fluorodeoxyglucose; FAPI-42-PCI = PCI obtained from 18F-FAPI-42 PET/CT; FDG-PCI = PCI obtained from 18F-FDG PET/CT; Surgery-PCI = PCI obtained from Surgery; CC-0 = complete cytoreduction with no visible disease. The ICC between 18F-FAPI-42 PCI and intraoperative PCI in all 48 patients was 0.915 (P < 0.01), which was substantially greater than that between 18F-FDG PCI and intraoperative PCI (ICC: 0.724, P < 0.01), as shown in Figure 2B. The ICC between 18F-FAPI-42 PCI and intraoperative PCI in 24 CC-0 patients was 0.78 (P < 0.01), which was not significantly different from that between 18F-FDG PCI and intraoperative PCI (ICC: 0.77, P < 0.01), as shown in Figure 2C. The ICC between 18F-FAPI-42 PCI and intraoperative PCI in 24 non-CC-0 patients was 0.94 (P < 0.01), which was substantially greater than that between 18F-FDG PCI and intraoperative PCI (ICC: 0.73, P < 0.01), as shown in Figure 2D. The preoperative imaging data of two typical cases of PM of colon cancer are shown in Figures 3 and 4. Images of a 30-year-old male with newly diagnosed sigmoid colon cancer who underwent 18F-FAPI-42 and 18F-FDG PET/CT for initial staging. (A)–(D) 18F-FDG PET/CT revealed peritoneal metastasis with mild uptake (SUV max = 3.1, white arrows on axial fusion images). (E)–(H) 18F-FAPI-42 PET/CT revealed more lesions and considerably greater radiotracer uptake than 18F-FDG PET/CT did (SUV max = 9.6, white arrows on axial fusion images). (I) Surgical view confirmed the presence of multiple lesions involving the diaphragm in the right upper region (arrow heads). (J) Postoperative pathology confirmed poorly differentiated adenocarcinoma. (K) FAP expression in tumor tissue. 18F = fluorine-18, FAPI = fibroblast activation protein-specific inhibitor, FDG = fluorodeoxyglucose, PET/CT = positron emission tomography/computed tomography, SUV max = maximum standardized uptake value, FAP = fibroblast activation protein. Images of a 46-year-old female with a history of laparoscopic rectal cancer radical resection who underwent 18F-FAPI-42 and 18F-FDG PET/CT. (A)–(D) Images from 18F-FDG PET/CT showed implantation metastasis of the omentum (SUV max = 2.2, white arrows on axial fusion images) and normal findings in the mesentery. (E)–(H) Images obtained at 18F-FAPI-42 PET/CT demonstrated both omentum and mesentery metastasis with greater radiotracer uptake than 18F-FDG (SUV max = 5.6, white arrows on axial fusion images). (I) Intraoperatively, peritoneal metastasis was found in the central region (arrow heads). (J) Postoperative pathology confirmed metastatic mucinous adenocarcinoma. (K) FAP expression in tumor tissue. 18F = fluorine-18, FAPI = fibroblast activation protein-specific inhibitor, FDG = fluorodeoxyglucose, PET/CT = positron emission tomography/computed tomography, SUV max = maximum standardized uptake value. Patient survival and prognosis Among the 48 surgical patients, OS and PFS were calculated through a 9-month follow-up period, as shown in Figure 5A and B. At the 9-month postoperative follow-up, the OS rate of the 48 surgical patients was 73.3% and the PFS rate was 31.6%, with a median PFS time of 5 months. The OS rates of patients with CC-0 cytoreduction and those without CC-0 cytoreduction are shown in Figure 5C. By the end of the 9-month post-surgery period, the OS rate of the CC-0 cytoreduction group was 95.6%; only one patient in this group experienced tumor progression, resulting in death. For the non-CC-0 cytoreduction group, the survival rate was 45.0%, with a median OS time of 8.5 months. The PFS for patients with CC-0 cytoreduction and those without CC-0 cytoreduction is shown in Figure 5D. By the end of the 9-month post-surgery period, the PFS rate of the CC-0 cytoreduction group was 40.9%; for the non-CC-0 cytoreduction group, the PFS rate was 25.0%. ROC curves and survival outcomes of the surgical patients. (A) OS curves of surgical patients (n = 48). (B) PFS curves of surgical patients (n = 48). (C) OS curves of CC-0 (n = 23) and Non-CC-0 (n = 20). (D) PFS curves of CC-0 (n = 22) and Non-CC-0 (n = 16). (E) ROC curves for predicting CC-0 resection. (F) PFS curves for patients with PCI > 18 and PCI ≤ 18 as identified by 18F-FAPI-42 PET/CT. ROC = receiver-operating characteristic, OS = overall survival, PFS = progression-free survival rate, CC-0 = complete cytoreduction with no visible disease. The ability to predict CC-0 using the PCI based on PET/CT was investigated by using ROC curve analysis (Figure 5E). The cut-off values of the PCI for 18F-FAPI-42 PET/CT and 18F-FDG PET/CT to predict CC-0 were <18 and <10, with AUCs of 0.80 and 0.79, respectively. The median PFS for patients with a PCI score of ≤18 on 18F-FAPI-42 PET/CT was 6 months whereas, for those with a PCI score of >18, it was 4 months. At 11 months post-surgery, the PFS rates for the patients with a PCI score of ≤18 and those with a PCI score of >18 were 11.7% and 0%, respectively (Figure 5F). Discussion This study explored the diagnostic efficiency of 18F-FAPI-42 PET/CT for patients with PM of colorectal cancer and its superiority in guiding treatment approaches; this was the first study to have performed CC-0 cytoreduction for PM based on 18F-FAPI-42 PET/CT and conducted pathological validation according to peritoneal regions. Previous studies have shown the importance of FAPI PET/CT in the diagnosis of primary and metastatic lesions in gastric, ovarian, and lung cancers [8, 9, 11, 16, 18, 19]. However, the radioisotope used in most previous studies was 68Ga. Compared with 68Ga, 18F has a longer half-life and high positron energy, and is a widely accepted radionuclide for imaging in clinical practice [20]. Furthermore, compared with 68Ga, 18F has a higher yield and lower production costs [21]. Previous research has compared the diagnostic value of the PCI score and Eisenkop score in the diagnosis of PM in advanced ovarian cancer using 18F-FDG PET/CT [22]. In this study, considering that the PCI score offers more detailed regional information and has a wider range of clinical applications, we evaluated the diagnostic efficiency of 18F-FAPI-42 PET/CT in colorectal cancer PM using the PCI score. Based on abdominal region, the sensitivity, NPV, and accuracy of 18F-FAPI-42 PET/CT were significantly higher than those of 18F-FDG PET/CT in the right upper (92.9% vs 39.3%, P < 0.01; 90.0% vs 52.8%, P < 0.01; 91.7% vs 62.5%, P < 0.01) and epigastrium regions (92.9% vs 42.6%, P < 0.01; 90.0% vs 58.8%, P = 0.01; 91.7% vs 66.7%, P < 0.01). The liver is primarily located in these regions and 18F-FDG PET/CT has a high background intensity in the liver, which could affect the detection of metastatic tumors on the liver capsule by 18F-FDG PET/CT, thereby reducing the diagnostic efficacy of 18F-FDG PET/CT in these regions [23]. In the small intestine, the diagnostic efficacy of 18F-FAPI-42 PET/CT was also higher than that of 18F-FDG PET/CT, which may account for the lower diagnostic efficacy of CT and 18F-FDG PET/CT in identifying metastatic tumors in the small intestinal mesentery in clinical practice [24–26], enabling surgeons to conduct more precise surgical exploration of these two regions. PM is a common form of metastasis in colorectal cancer and previous studies have shown that 18F-FDG PET/CT sometimes has low to moderate sensitivity in detecting peritoneal metastatic lesions, possibly due to physiological intestinal uptake [27, 28]. Recent studies have shown that 68Ga-FAPI-42 PET/CT is superior to 18F-FDG PET/CT in diagnosing colorectal cancer, as there is no physiological uptake of FAPI in the intestines [8, 29]. The present study indicates that, for patients with PM of colorectal cancer, the PCI score indicated by 18F-FAPI-42 PET/CT was more strongly consistent with the intraoperative score than 18F-FDG PET/CT. For patients who achieved CC-0 cytoreduction, both 18F-FDG PET/CT and 18F-FDG PET/CT provided good diagnostic efficacy. However, for patients who did not undergo CC0 cytoreduction, the PCI score indicated by 18F-FAPI-42 PET/CT had a stronger consistency with the intraoperative PCI score than that indicated by 18F-FDG PET/CT. This may be because patients with non-CC-0 cytoreduction have more extensive PMs and a greater tumor burden; thus, the superior diagnostic efficacy of FAPI can be better demonstrated. However, false-positive uptake of 18F-FAPI-42 PET/CT was also detected. Among the included patients, four cases (patient IDs of 1, 15, 24, 25) presented high uptake on preoperative 18F-FAPI-42 PET/CT, suggesting the possibility of metastatic tumors, but intraoperative exploration and postoperative pathology confirmed one case as an abscess, one case as colostomy tissue, and two cases as fibrofatty tissue. This may be the result of the uptake of FAPI by inflammatory and non-specific fibrotic tissue [12, 13]. In addition, this study revealed that the molecular subtype of targeted therapy may affect the expression of 18F-FDG and 18F-FAPI-42. In our study, four patients (patient IDs of 13, 14, 30, 42) who were receiving targeted therapy during the preoperative treatment process had low or no expression of 18F-FDG or 18F-FAPI-42 on PET/CT. However, intraoperative exploration reveals tumor metastasis to the peritoneum, which is inconsistent with the preoperative PET/CT findings. Previous studies have shown that FAPI uptake in recurrent or metastatic gastro-intestinal stromal tumors was not related to tumor size, degree of enhancement, gene mutation type, or targeted therapy, whereas FDG expression was related to tumor size, gene mutation type, or targeted therapy [19], which is contrary to our research results. This may be because different drugs have different targets and exert different effects on the microenvironments of various types of tumors [30, 31]. Besides, due to the massive bilateral ovarian metastatic tumors and the high uptake of 18F-FAPI-42 of the inflammatory scar tissue in the peritoneum (patient ID: 34), nuclear medicine physicians mistakenly rated some negative areas as positive in PET/CT scoring, resulting in significant errors. In the CC-0 group, the patients with a PCI score of ≤18 on 18F-FAPI-42 PET/CT had a median PFS of 6 months, whereas those with a PCI score of >18 had a median PFS of 4 months. At 11 months post-surgery, the PFS rates for the group with a PCI score of ≤18 and the group with a PCI score of >18 were 11.7% and 0%, respectively (Figure 5F). This suggests that it can more accurately guide CRS to achieve CC-0 cytoreduction when 18F-FAPI-42 PET/CT indicates a PCI score of ≤18. However, in three cases (patient IDs: 10, 44, 48) with a PCI score of ≤18 on18F-FAPI-42 PET/CT, CC-0 cytoreduction was not achieved due to the invasion of the pancreas head (patient ID: 10) and severe abdominal adhesion (patient IDs: 44, 48). For patients who achieved CC-0 cytoreduction, postoperative HIPEC followed by systemic chemotherapy significantly improved survival time [32, 33]. In our study, among the 24 patients who achieved CC-0 cytoreduction guided by 18F-FAPI-42 PET/CT, only 1 patient died due to tumor progression during the 9-month follow-up period after receiving HIPEC and postoperative chemotherapy, resulting in a survival rate of 95.6%. Among the remaining 24 patients who did not achieve CC-0 cytoreduction, 11 died from tumor progression within 9 months postoperatively, resulting in a survival rate of 45.0%. The median survival time was 8.5 months (Figure 5C) and all these patients had a high extent of PM. This aligns with results of previous studies, which reported a median OS of 6–9 months [4]. In the present study, for patients with PM of colorectal cancer, treatment modalities can be selected based on the PCI score suggested by 18F-FAPI-42 PET/CT. When the PCI score is ≤18, CRS can be chosen to achieve CC-0 cytoreduction followed by a combination of HIPEC and systemic chemotherapy, extending the patient’s survival time. When 18F-FAPI-42 PET/CT suggests that the PCI is >18, selective palliative surgery or chemotherapy can be considered. For patients with unclear PM scores, the use of 18F-FAPI-42 PET/CT can effectively avoid unnecessary laparoscopic explorations, reduce patient suffering, and reduce costs. Our study also has certain limitations. First, the sample size included in our study was small. We quickly collected 48 samples over 9 months and our sample size is still growing. Second, the diagnostic efficacy of the two PET/CT methods for the detection of PM in patients with colorectal cancer also needs further validation, as it was based on our sample size. Therefore, multicenter studies with larger sample sizes are needed to validate this promising imaging technique. Furthermore, our follow-up duration was relatively short, but is still ongoing. Conclusions 18F-FAPI-42 PET/CT has superior diagnostic efficacy for patients with PM of colorectal cancer, particularly in the right upper quadrant, epigastrium, and small intestine. The PCI score of 18F-FAPI-42 PET/CT is very close to the intraoperative PCI score and has a high value for predicting CC-0. It can assist patients in obtaining more precise personalized treatment based on the 18F-FAPI-42 PCI score, improving patient prognosis. Supplementary Material Acknowledgements Supported by National Key Clinical Discipline. Supplementary Figure S1 for website: “https://www.home-for-researchers.com/static/index.html#/” for supplementary support. The authors thank Lea Moore, PhD, AJE, for English-language editing services. Contributor Information Xuneng Zhang, Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China; Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. Rongqin Zhang, Department of Nuclear Medicine, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China; Department of Nuclear Medicine, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China. Qingyang Zheng, Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China; Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. Zichuan He, Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China; Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. Bing Lan, Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China; Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. Yun Zhong, Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China; Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. Zhichao Huang, Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China; Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. Wei Fan, Department of Nuclear Medicine, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China. Hui Wang, Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China; Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China; Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. Keli Yang, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China; Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. Zhanwen Zhang, Department of Nuclear Medicine, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. Huaiming Wang, Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. Supplementary Data Supplementary data is available at Gastroenterology Report online. Authors’ Contributions X.Z., R.Z., and Q.Z. contributed equally to this study and should be considered co-first authors. X.Z. had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors have ensured the integrity of the entire study; all authors participated in the research concept/design or data collection or data analysis/interpretation; all authors were involved in drafting or revising the manuscript for significant intellectual content; all authors submitted the final version of the manuscript for approval; all authors agreed to ensure that any issues related to the work were properly resolved; X.Z., R.Z., and Q.Z. conducted the literature research; X.Z. and R.Z. completed the statistical analysis; and X.Z., R.Z., and H.W. handled the manuscript editing. All authors have read and approved the final manuscript. Funding H.W. has received grants from the National Natural Science Foundation of China [grant no. 82103084] and the Dongguan Science and Technology of Social Development Program [grant no. 20231800904303]. Z.Z. has received grants from the National Natural Science Foundation of China [no. 81901772], the Natural Science Foundation of Guangdong Province [nos 2019A1515011893, 2023A1515011300], and the State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia & The First People’s Hospital of Kashi Fund [no. SKL-HIDCA-2020-KS2]. H.W. has received grants from the Xinjiang Autonomous Region Technology Plan [grant no. 2022E02125] and The Sixth Affiliated Hospital of Sun Yat-Sen University Clinical Research–1010 Program: 1010CG (2022)–08. K.Y. has received grants from the National Natural Science Foundation of China [grant no. 82300619] and the Science and Technology Projects in Guangzhou [grant no. 2023A04J2245]. Conflicts of Interest The authors declare that there are no conflicts of interest associated with this study. Data Availability The datasets analysed during the current study are available from the corresponding author upon reasonable request. References Associated Data Supplementary Materials Data Availability Statement The datasets analysed during the current study are available from the corresponding author upon reasonable request.